These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29939161)

  • 1. HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer.
    Alyamani M; Emamekhoo H; Park S; Taylor J; Almassi N; Upadhyay S; Tyler A; Berk MP; Hu B; Hwang TH; Figg WD; Peer CJ; Chien C; Koshkin VS; Mendiratta P; Grivas P; Rini B; Garcia J; Auchus RJ; Sharifi N
    J Clin Invest; 2018 Aug; 128(8):3333-3340. PubMed ID: 29939161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.
    Hettel D; Sharifi N
    Nat Rev Urol; 2018 Mar; 15(3):191-196. PubMed ID: 29231195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer.
    Hahn AW; Gill DM; Nussenzveig RH; Poole A; Farnham J; Cannon-Albright L; Agarwal N
    Clin Genitourin Cancer; 2018 Aug; 16(4):288-292. PubMed ID: 29674118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.
    Almassi N; Reichard C; Li J; Russell C; Perry J; Ryan CJ; Friedlander T; Sharifi N
    JAMA Oncol; 2018 Apr; 4(4):554-557. PubMed ID: 29049452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone.
    Shiota M; Narita S; Akamatsu S; Fujimoto N; Sumiyoshi T; Fujiwara M; Uchiumi T; Habuchi T; Ogawa O; Eto M
    JAMA Netw Open; 2019 Feb; 2(2):e190115. PubMed ID: 30794306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer.
    Wu G; Huang S; Nastiuk KL; Li J; Gu J; Wu M; Zhang Q; Lin H; Wu D
    Prostate; 2015 May; 75(7):777-782. PubMed ID: 25731771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer.
    Han FF; Ren LL; Xuan LL; Lv YL; Liu H; Gong LL; An ZL; Liu LH
    Cancer Chemother Pharmacol; 2021 Jan; 87(1):103-112. PubMed ID: 33141329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.
    Hearn JWD; AbuAli G; Reichard CA; Reddy CA; Magi-Galluzzi C; Chang KH; Carlson R; Rangel L; Reagan K; Davis BJ; Karnes RJ; Kohli M; Tindall D; Klein EA; Sharifi N
    Lancet Oncol; 2016 Oct; 17(10):1435-1444. PubMed ID: 27575027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.
    Lu C; Terbuch A; Dolling D; Yu J; Wang H; Chen Y; Fountain J; Bertan C; Sharp A; Carreira S; Isaacs WB; Antonarakis ES; De Bono JS; Luo J
    Ann Oncol; 2020 Sep; 31(9):1178-1185. PubMed ID: 32387417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AR Signaling in Prostate Cancer Regulates a Feed-Forward Mechanism of Androgen Synthesis by Way of HSD3B1 Upregulation.
    Hettel D; Zhang A; Alyamani M; Berk M; Sharifi N
    Endocrinology; 2018 Aug; 159(8):2884-2890. PubMed ID: 29850791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline HSD3B1 Genetics and Prostate Cancer Outcomes.
    Thomas L; Sharifi N
    Urology; 2020 Nov; 145():13-21. PubMed ID: 32866512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance.
    Sharifi N; Diaz R; Lin HM; Roberts E; Horvath LG; Martin A; Stockler MR; Yip S; Subhash VV; Portman N; Davis ID; Sweeney CJ
    J Clin Invest; 2024 Sep; 134(18):. PubMed ID: 39286977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer.
    Hearn JWD; Sweeney CJ; Almassi N; Reichard CA; Reddy CA; Li H; Hobbs B; Jarrard DF; Chen YH; Dreicer R; Garcia JA; Carducci MA; DiPaola RS; Sharifi N
    JAMA Oncol; 2020 Apr; 6(4):e196496. PubMed ID: 32053149
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Zein J; Gaston B; Bazeley P; DeBoer MD; Igo RP; Bleecker ER; Meyers D; Comhair S; Marozkina NV; Cotton C; Patel M; Alyamani M; Xu W; Busse WW; Calhoun WJ; Ortega V; Hawkins GA; Castro M; Chung KF; Fahy JV; Fitzpatrick AM; Israel E; Jarjour NN; Levy B; Mauger DT; Moore WC; Noel P; Peters SP; Teague WG; Wenzel SE; Erzurum SC; Sharifi N
    Proc Natl Acad Sci U S A; 2020 Jan; 117(4):2187-2193. PubMed ID: 31932420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer.
    Shiota M; Akamatsu S; Narita S; Sumiyoshi T; Fujiwara M; Uchiumi T; Ogawa O; Habuchi T; Eto M
    Pharmacogenomics J; 2021 Aug; 21(4):440-445. PubMed ID: 33649516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer.
    Hearn JWD; Xie W; Nakabayashi M; Almassi N; Reichard CA; Pomerantz M; Kantoff PW; Sharifi N
    JAMA Oncol; 2018 Apr; 4(4):558-562. PubMed ID: 29049492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of 3β-hydroxysteroid dehydrogenases and their clinical use in prostate cancer.
    Shiota M; Endo S; Tsukahara S; Tanegashima T; Kobayashi S; Matsumoto T; Eto M
    Endocr Relat Cancer; 2024 Jul; 31(7):. PubMed ID: 38688318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral androgen biosynthesis associated with 3β-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer.
    Ganguly S; Lone Z; Muskara A; Imamura J; Hardaway A; Patel M; Berk M; Smile TD; Davicioni E; Stephans KL; Ciezki J; Weight CJ; Gupta S; Reddy CA; Tendulkar RD; Chakraborty AA; Klein EA; Sharifi N; Mian OY
    J Clin Invest; 2023 Nov; 133(22):. PubMed ID: 37966114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.
    Hanamura T; Niwa T; Nishikawa S; Konno H; Gohno T; Tazawa C; Kobayashi Y; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
    Breast Cancer Res Treat; 2013 Jun; 139(3):731-40. PubMed ID: 23780684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.
    Khalaf DJ; Aragón IM; Annala M; Lozano R; Taavitsainen S; Lorente D; Finch DL; Romero-Laorden N; Vergidis J; Cendón Y; Oja C; Pacheco MI; Zulfiqar M; ; Gleave ME; Wyatt AW; Olmos D; Chi KN; Castro E
    Ann Oncol; 2020 Sep; 31(9):1186-1197. PubMed ID: 32574722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.